Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303281 | 1.00 | KMT2A (0.51) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL3301411 | 0.89 | KMT2A (0.51) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL3301417 | 0.89 | KMT2A (0.51) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL13389840 | 0.88 | KMT2A (0.51) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL14113707 | 0.88 | KMT2A (0.51) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL3302704 | 0.88 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1RAB9A | |
| SCHEMBL3302702 | 0.88 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1RAB9A | |
| SCHEMBL14113715 | 0.88 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1RAB9A | |
| SCHEMBL14113558 | 0.86 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1PDE4A | |
| SCHEMBL3298768 | 0.86 | KMT2A (0.63) | KMT2AMEN1MAPTALDH1A1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | KMT2A 1665/4885MEN1 2505/4885MAPT 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.